A synthetic luteinizing hormone releasing hormone vaccine II. Temporal aspects of titer development and formulation trials in BALB/c mice.
Cysteine substituted analogues of luteinizing hormone releasing hormone (LHRH) were coupled to carrier molecules, and the resulting conjugates used to characterize the immune response to native LHRH generated in BALB/c mice and to formulate vaccines in an effort to maximize titer development. In an active immunization trial designed to characterize temporal aspects of anti-LHRH titer development, titers could be detected 1 week after initial immunization. No differences were observed in response between male and female mice. Booster immunizations could enhance the titers against LHRH. The titers developed against the carrier molecule were uniformly higher than the corresponding anti-LHRH titers throughout the course of the trial. In separate trials, vaccines were formulated and tested in BALB/c mice for titer development against LHRH. Adjuvants, carrier molecules, dosage and peptide to carrier ratio were considered. Dosages of 50 micrograms conjugate per immunization per mouse, at conjugation ratios of 3-12 peptides per 10(5) Da carrier molecule, were found to produce immune responses. Adjuvants including Havlogen and dimethyldioctadecylammonium bromide (DDA), and carrier molecules including keyhole limpet hemocyanin (KLH), porcine thyroglobulin (TGB) and equine gamma globulin (EGG) were all found to be effective.